XORTX Therapeutics (XORTX Therapeutics) Accounts Payable & Accrued Expense : $0.53 Mil (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Accounts Payable & Accrued Expense?

XORTX Therapeutics's quarterly accounts payable & accrued expense declined from Mar. 2023 ($0.54 Mil) to Jun. 2023 ($0.36 Mil) but then increased from Jun. 2023 ($0.36 Mil) to Sep. 2023 ($0.53 Mil).

XORTX Therapeutics's annual accounts payable & accrued expense declined from Dec. 2020 ($0.81 Mil) to Dec. 2021 ($0.55 Mil) but then increased from Dec. 2021 ($0.55 Mil) to Dec. 2022 ($1.45 Mil).

XORTX Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for XORTX Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Accounts Payable & Accrued Expense Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.59

0.88

0.81

0.55

1.45

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1.36	1.45	0.54	0.36	0.53

XORTX Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.